Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow SANGAMO THERAPEUTICS, INC

Get SEC filing alerts via email and in your feed for SANGAMO THERAPEUTICS, INC

SGMO

SANGAMO THERAPEUTICS, INC

About SANGAMO THERAPEUTICS, INC

Sangamo Therapeutics is a genomic medicine company specializing in gene regulation and editing technologies. Its core focus includes developing epigenetic therapies and innovative AAV capsids for neurological diseases, as well as gene therapies for rare conditions like Fabry disease and hemophilia A. The company leverages zinc finger platforms and proprietary delivery systems to create targeted, potentially curative treatments for serious genetic and neurodegenerative disorders.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from SANGAMO THERAPEUTICS, INC

1
1
SANGAMO THERAPEUTICS, INC Sangamo Therapeutics Reports 77.6% Revenue Decline in Q1 2026

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
SANGAMO THERAPEUTICS, INC Sangamo Therapeutics Reports $122.9 Million Net Loss in 2025 Amid Strategic Shift

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
SANGAMO THERAPEUTICS, INC Sangamo Therapeutics Reports 98.8% Revenue Decline and Financial Challenges

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
SANGAMO THERAPEUTICS, INC Sangamo Therapeutics Reports $18.3 Million Revenue for Q2 2025 Amid Significant Losses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
SANGAMO THERAPEUTICS, INC Sangamo Therapeutics Reports 1,238% Revenue Increase to $6.4 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
SANGAMO THERAPEUTICS, INC Sangamo Therapeutics Reports $97.9 Million Net Loss and Decreased Revenues in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
SANGAMO THERAPEUTICS, INC Sangamo Therapeutics Reports Mixed Financial Results, Seeks Additional Capital Amid Restructuring Efforts

Via official filing (AI summary) | over 1 year ago | 0 comments